Last reviewed · How we verify
CITALOPRAM HYDROBROMIDE
CITALOPRAM HYDROBROMIDE is a drug. It is currently FDA-approved (first approved 1998) for Major Depressive Disorder (MDD).
Citalopram hydrobromide is a small molecule inhibitor of the sodium-dependent serotonin transporter, classified as an inhibitor. It is used to treat conditions such as depression, obsessive-compulsive disorder, and panic disorder, among others.
At a glance
| Generic name | CITALOPRAM HYDROBROMIDE |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1998 |
Approved indications
- Major Depressive Disorder (MDD)
Boxed warnings
- WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors [see Warnings and Precautions (5.1) ] . Citalopram is not approved for use in pediatric patients [see Use in Specific Populations (8.4) ]. WARNING: SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning. Increased risk of suicidal thoughts and behavior in pediatric and young adult patients taking antidepressants. Closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors ( 5.1 ) . Citalopram is not approved for use in pediatric patients ( 8.4 ).
Common side effects
- Ejaculation disorder
- Nausea
- Insomnia
- Dizziness
- Somnolence
- Asthenia
- Dry mouth
- Vomiting
- Agitation
Serious adverse events
- Suicidal thoughts and behaviors
- QT-prolongation and torsade de pointes
- Serotonin syndrome
- Seizures
- Hyponatremia
- Angle-closure glaucoma
- Activation of mania or hypomania
- Increased risk of bleeding
- Discontinuation syndrome
- Hypersensitivity reactions
Key clinical trials
- Citalopram as a Posterior Cortical Protective Therapy in Parkinson Disease (PHASE2)
- A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats
- Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
- Citalopram and the Risk of Serious Adverse Events
- Τhe Combination of Pharmacotherapy With RECOVERYTRSGR and RECOVERYTRSBDGR. (PHASE4)
- Effect of SC-ICBT for Adults With OCD：A Three-Arm Randomized Controlled Trial (NA)
- Cellular Aging and Neurobiology of Depression Study (NA)
- Effects of Intravenous (IV) Citalopram Hydrochloride During Transcranial Magnetic Stimulation in Major Depressive Disorder (MDD) (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CITALOPRAM HYDROBROMIDE CI brief — competitive landscape report
- CITALOPRAM HYDROBROMIDE updates RSS · CI watch RSS
Frequently asked questions about CITALOPRAM HYDROBROMIDE
What is CITALOPRAM HYDROBROMIDE?
What is CITALOPRAM HYDROBROMIDE used for?
When was CITALOPRAM HYDROBROMIDE approved?
What development phase is CITALOPRAM HYDROBROMIDE in?
What are the side effects of CITALOPRAM HYDROBROMIDE?
Related
- Indication: Drugs for Major Depressive Disorder (MDD)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing